Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chloride channel protein 4 (CLCN4) is a member of the CLC family of chloride channels and chloride/proton exchangers. It is primarily an electrogenic H(+)/Cl(-) exchanger that mediates the exchange of chloride ions for protons across intracellular membranes, especially in endosomal and organellar compartments. CLCN4 is highly expressed in the brain and is thought to play roles in ion homeostasis, endosomal pH regulation, and intracellular trafficking. Mutations in CLCN4 are associated with X-linked neurodevelopmental disorders including intellectual disability, early-onset epilepsy, behavioral and movement disorders, and microcephaly. The CLCN4 gene is located on the X chromosome at Xp22.3, and both loss- and gain-of-function mutations have been observed in patients, leading to complex clinical phenotypes. As of now, no drugs are approved that specifically modulate CLCN4, and it is considered an emerging target for rare genetic disorders rather than for common, druggable diseases.
Not applicable (no known drugs); theoretical mechanisms would involve modulation of chloride–proton antiport activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chloride channel protein 4 (CLCN4).